Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
D. Ross Camidge(University of Colorado Denver), Sanjay Popat(Royal Marsden NHS Foundation Trust), Masashi Kondo(Fujita Health University), Ji‐Youn Han(National Cancer Centre Japan), Myung‐Ju Ahn(Samsung Medical Center), Takayuki Asato(Takeda (Japan)), Robert J. Fram, Yuichiro Ohe(National Cancer Center), James Chih‐Hsin Yang(National Taiwan University Hospital), Angelo Delmonte(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Kentarou Kudou(Takeda (Japan)), Florin Vranceanu(Takeda (United States)), Shunichi Sugawara(Sendai Kousei Hospital), Hye Ryun Kim(Yonsei University), Ki Hyeong Lee(Chungbuk National University Hospital), Bradley Hupf(Takeda (United States)), Maximilian J. Hochmair(Karl Landsteiner Society)
Cited by 3
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k